The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Income tax expense increased by $6.7 million in 2024 compared to 2023, primarily due to an increase in U.S. taxes under the ...

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

Gireesh Babu, New Delhi Wednesday, March 5, 2025, 14:45 Hrs [IST] With the registration of clinical research organisations (CROs) to b ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!

Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, ...

New EU Clinical Trial Regulations simplify international trials while offering the means to counter drug shortages for trials ...